On March 27, Gelonghui Biotech (300294.SZ) said on the investor interactive platform that the price of the company's products is stable. The cost of intravenous human immunoglobulin increased by 16.68% in 2023, mainly due to the increase in the revenue scale of this product.
博雅生物(300294.SZ)：公司产品价格稳定
Liberal Arts Biotech (300294.SZ): The price of the company's products is stable
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.